Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate

If you need more information please contact us, a member of the team will text you back as soon as possible.

1400 112th Ave SE,

Suite 100, Bellevue,

Washington 98004

 

info@arscience.com

 

Arscience Bio 2023

ARScience Bio’s team has over 20 years of experience in cytokine and immunomodulator development and manufacturing. We have built strong partnerships with leading academic institutions and clinical groups to develop novel indications for our portfolio of products.